ID

24891

Description

Study ID: 101468/166 Clinical Study ID: SKF-101468/166 Study Title: A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Parkinson Disease

Mots-clés

Versions (3)
  1. 22/08/2017 22/08/2017 -
  2. 22/08/2017 22/08/2017 -
  3. 04/09/2017 04/09/2017 -
Téléchargé le

22 août 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

randomization determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166

Anglais

randomization determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166

1 Formulaires  
Administrative Data
Description

Administrative Data

Alias
UMLS CUI-1
C1320722
Patient Initials
Description

patient's initials

Type de données

text

Alias
UMLS CUI [1]
C2986440
Patient No.
Description

patient number

Type de données

integer

Alias
UMLS CUI [1]
C1830427
Date of Visit
Description

date of visit

Type de données

date

Alias
UMLS CUI [1]
C1320303
RANDOMIZATION AND COHORT ASSIGNMENT
Description

RANDOMIZATION AND COHORT ASSIGNMENT

Alias
UMLS CUI-1
C0034656
After review of all eligibility criteria is the patient eligible for the study?
Description

patient eligible for clinical trial

Type de données

text

Alias
UMLS CUI [1]
C1302261
Randomization Number
Description

randomization numb

Type de données

integer

Alias
UMLS CUI [1]
C2986235
Retour au début de la page

Similar models

randomization determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Administrative Data
C1320722 (UMLS CUI-1)
patient's initials
Item
Patient Initials
text
C2986440 (UMLS CUI [1])
patient number
Item
Patient No.
integer
C1830427 (UMLS CUI [1])
date of visit
Item
Date of Visit
date
C1320303 (UMLS CUI [1])
Item Group
RANDOMIZATION AND COHORT ASSIGNMENT
C0034656 (UMLS CUI-1)
Item
After review of all eligibility criteria is the patient eligible for the study?
text
C1302261 (UMLS CUI [1])
patient eligible for clinical trial
Code List
After review of all eligibility criteria is the patient eligible for the study?
CL Item
Yes - Please telephone the Central Randomization Center to enroll the patient. Record the assigned (1)
CL Item
Randomization Number and check the appropriate box to indicate the assigned Cohort in the (Randomization Number and check the appropriate box to indicate the assigned Cohort in the)
CL Item
section below. (section below.)
CL Item
No - Record the reason for Screen Failure on the "Patient Screening/Enrollment Log." (2)
randomization numb
Item
Randomization Number
integer
C2986235 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial